Literature DB >> 11152308

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.

C R Meier1, P N Napalkov, Y Wegmüller, T Jefferson, H Jick.   

Abstract

This large population-based study using the UK-based General Practice Research Database was conducted to quantify influenza-related physician visits, clinical complications of and risk factors for influenza, and related drug use in all age groups from 1991 to 1996. A total of 141,293 subjects who had one or more diagnoses of influenza or influenza-like illness during the study period as well as the same number of age-, sex-, practice and calendar time-matched controls were identified. Adults aged 15-64 years had the highest influenza incidence rate. The risk of getting influenza was particularly increased for subjects with chronic respiratory conditions (asthma or chronic obstructive pulmonary disease, odds ratio 1.65, 95% confidence interval 1.60-1.70). Subjects with influenza were more likely to have a diagnosis of clinical complications than control subjects (relative risk 3.4, 95% confidence interval 3.3-3.6). The risk of developing clinical complications was highest for children and was elevated for subjects with certain underlying chronic conditions. In absolute terms, otherwise healthy adults (15-64 years) accounted for the greatest proportion of all influenza-related physician visits as well as clinical complications in this study population. Of the 141,293 subjects with influenza, 83,911 (59.4%) received drugs on prescription. The most frequently prescribed drugs were antibiotics (45.2%), followed by antipyretics/analgesics (22.5%). Influenza patients were approximately six times more likely to use drugs on prescription than controls. This analysis may lead to further analyses on the economic impact of influenza and the contribution of different population groups to that burden.

Entities:  

Mesh:

Year:  2000        PMID: 11152308     DOI: 10.1007/s100960000376

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  68 in total

1.  Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK.

Authors:  Hershel Jick; James A Kaye; Corri Black
Journal:  Br J Gen Pract       Date:  2004-05       Impact factor: 5.386

2.  Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.

Authors:  Majbrit Vindt Holm; Marlene Gyldmark; Ebba Holme Hansen
Journal:  Pharm World Sci       Date:  2004-12

3.  Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Authors:  Beate Sander; Frederick G Hayden; Marlene Gyldmark; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

Authors:  Michael Kurowski; Charles Oo; Hugh Wiltshire; Joanne Barrett
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

5.  Effectiveness of 2012-2013 influenza vaccine against influenza-like illness in general population: estimation in a French web-based cohort.

Authors:  Marion Debin; Vittoria Colizza; Thierry Blanchon; Thomas Hanslik; Clement Turbelin; Alessandra Falchi
Journal:  Hum Vaccin Immunother       Date:  2013-12-16       Impact factor: 3.452

6.  Costs associated with influenza-related hospitalization in the elderly.

Authors:  Núria Torner; Encarna Navas; Núria Soldevila; Diana Toledo; Gemma Navarro; Aurea Morillo; Maria José Pérez; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

Review 7.  The impact of influenza on working days lost: a review of the literature.

Authors:  Martin Keech; Paul Beardsworth
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.

Authors:  Ming-Chin Yang; Elise Chia-Hui Tan; Jian-Jhih Su
Journal:  Hum Vaccin Immunother       Date:  2016-09-13       Impact factor: 3.452

9.  Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.

Authors:  Beate Sander; Azhar Nizam; Louis P Garrison; Maarten J Postma; M Elizabeth Halloran; Ira M Longini
Journal:  Value Health       Date:  2008-07-30       Impact factor: 5.725

Review 10.  Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients.

Authors:  Regina Dutkowski
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.